Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A clinical study of TG-1000 for the treatment of influenza A and B

Next Previous
X
Search
Trial Profile

A clinical study of TG-1000 for the treatment of influenza A and B

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 04 Nov 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs TG-1000 (Primary)
  • Indications Influenza A virus infections; Influenza B virus infections; Influenza virus infections
  • Focus Adverse reactions
  • Sponsors TaiGen Biotechnology

    • Most Recent Events

    • 04 Nov 2020 New trial record
    • 01 Nov 2020 According to a TaiGen Biotechnology media release, that U.S. Food and Drug Administration (FDA) has approved the Investigation New Drug (IND) application for TG-1000, a novel treatment for influenza A and B. With the IND approval in place, the company expects to extend the clinical study of TG-1000 to the U.S. in the near future.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top